[Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)].
The aim of the study was to assess the frequency of serum Ab-anti-p53 in 39 patients with advanced NSCLC and to evaluate the predictive value of the test. Antibodies were present in 10 (25.6%) of patients. There was no correlation between Ab-anti-p53 and clinical characteristics including age, gender, and histological type of tumor. In 17 patients response to chemotherapy (CT) was obtained (in one patient--complete, and in 16--partial response). The percentage of patients responding to CT in group with and without serum antibodies did not differ significantly (33% and 48%, respectively; p = 0.48). The results of the study indicate that serum Ab-anti-p53 are relatively often present in advanced NSCLC patients, however the clinical value of this test needs further evaluation.
Skrzypski
Marcin
M
Klinika Chorób Płuc i Gruźlicy AM, Gdańsku.
Szymanowska
Amelia
A
Janowicz
Anna
A
Dziadziuszko
Rafał
R
Ramlau
Rodryg
R
Kozielski
Jerzy
J
Pilarska-Machowicz
Anna
A
Dobrzańska
Zuzanna
Z
Bigda
Jacek
J
Krzakowski
Maciej
M
Jassem
Ewa
E
Jassem
Jacek
J
D000328:Adult; D000368:Aged; D000912:Antibodies, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53
Wystepowanie przeciwciał przeciw białku p53 w surowicy chorych na zaawansowanego niedrobnokomórkowego raka płuca. Doniesienie wstepne.